TY - JOUR
T1 - IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation
AU - Hong, Lih En
AU - Wechalekar, Mihir D.
AU - Kutyna, Monika
AU - Small, Annabelle
AU - Lim, Kelly
AU - Thompson-Peach, Chloe
AU - Li, Joule J.
AU - Chhetri, Rakchha
AU - Scott, Hamish S.
AU - Brown, Anna
AU - Hahn, Christopher N.
AU - Yeung, David T.
AU - Sajid, Salvia
AU - Robinson, Nirmal
AU - Thomas, Ranjeny
AU - Branford, Susan
AU - D'Andrea, Richard J.
AU - Samaraweera, Saumya E.
AU - Patnaik, Mrinal
AU - Proudman, Susanna
AU - Thomas, Daniel
AU - Kok, Chung Hoow
AU - Shah, Mithun V.
AU - Hiwase, Devendra K.
N1 - Publisher Copyright:
© 2024 American Society of Hematology
PY - 2024
Y1 - 2024
N2 - High prevalence of IDH mutations in seronegative rheumatoid arthritis (RA) with myeloid neoplasm, elevated 2-hydroxyglutarate, dysregulated innate immunity, and proinflammatory microenvironment suggests causative association between IDH mutations and seronegative RA. Our findings merit investigation of IDH inhibitors as therapeutics for seronegative IDH-mutated RA.
AB - High prevalence of IDH mutations in seronegative rheumatoid arthritis (RA) with myeloid neoplasm, elevated 2-hydroxyglutarate, dysregulated innate immunity, and proinflammatory microenvironment suggests causative association between IDH mutations and seronegative RA. Our findings merit investigation of IDH inhibitors as therapeutics for seronegative IDH-mutated RA.
UR - http://www.scopus.com/inward/record.url?scp=85188022438&partnerID=8YFLogxK
U2 - 10.1182/blood.2023023593
DO - 10.1182/blood.2023023593
M3 - Article
C2 - 38457663
AN - SCOPUS:85188022438
SN - 0006-4971
JO - Blood
JF - Blood
ER -